KR102331422B1 - 아이소인돌린 조성물 및 신경퇴행성 질환을 치료하는 방법 - Google Patents
아이소인돌린 조성물 및 신경퇴행성 질환을 치료하는 방법 Download PDFInfo
- Publication number
- KR102331422B1 KR102331422B1 KR1020167023951A KR20167023951A KR102331422B1 KR 102331422 B1 KR102331422 B1 KR 102331422B1 KR 1020167023951 A KR1020167023951 A KR 1020167023951A KR 20167023951 A KR20167023951 A KR 20167023951A KR 102331422 B1 KR102331422 B1 KR 102331422B1
- Authority
- KR
- South Korea
- Prior art keywords
- sigma
- salt
- compound
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(*)(CCc1c(*)c(*)c(*)c(*)c1*)N(C1)Cc2c1c(*)c(*)c(*)c2* Chemical compound *C(*)(CCc1c(*)c(*)c(*)c(*)c1*)N(C1)Cc2c1c(*)c(*)c(*)c2* 0.000 description 5
- WIBVYMDDPOXFEA-CQSZACIVSA-N C[C@H](CCc(cc1)cc(OC)c1O)N(C1)Cc2c1cccc2S(C)(=O)=O Chemical compound C[C@H](CCc(cc1)cc(OC)c1O)N(C1)Cc2c1cccc2S(C)(=O)=O WIBVYMDDPOXFEA-CQSZACIVSA-N 0.000 description 2
- PAMRCPLHRDFSTB-CYBMUJFWSA-N C[C@H](CCc(cc1)cc(OC)c1O)N1Cc2cc(C(F)(F)F)ccc2C1 Chemical compound C[C@H](CCc(cc1)cc(OC)c1O)N1Cc2cc(C(F)(F)F)ccc2C1 PAMRCPLHRDFSTB-CYBMUJFWSA-N 0.000 description 2
- RCAWYRTWTRRNST-OAHLLOKOSA-N C[C@H](CCc(cc1)cc(OC)c1OCCO)N(Cc1ccc2)Cc1c2F Chemical compound C[C@H](CCc(cc1)cc(OC)c1OCCO)N(Cc1ccc2)Cc1c2F RCAWYRTWTRRNST-OAHLLOKOSA-N 0.000 description 2
- ISQAPFMBJFZOLG-UHFFFAOYSA-N CC(C)(C)Oc1cc(CCC(C)(C)N(C2)Cc3c2ccc(S(C)(=O)=O)c3)ccc1O Chemical compound CC(C)(C)Oc1cc(CCC(C)(C)N(C2)Cc3c2ccc(S(C)(=O)=O)c3)ccc1O ISQAPFMBJFZOLG-UHFFFAOYSA-N 0.000 description 1
- NOIWIZKAQFHHLU-UHFFFAOYSA-N CC(C)(C)Oc1cc(CCC(C)(C)N2Cc3cc(S(C)(=O)=O)ccc3C2)ccc1OC(C)=O Chemical compound CC(C)(C)Oc1cc(CCC(C)(C)N2Cc3cc(S(C)(=O)=O)ccc3C2)ccc1OC(C)=O NOIWIZKAQFHHLU-UHFFFAOYSA-N 0.000 description 1
- HSHMBUQZFMQWOY-UHFFFAOYSA-N CC(C)(C)Oc1ccc(CCC(C)(C)N(C2)Cc3c2ccc(S(C)(=O)=O)c3)cc1OC Chemical compound CC(C)(C)Oc1ccc(CCC(C)(C)N(C2)Cc3c2ccc(S(C)(=O)=O)c3)cc1OC HSHMBUQZFMQWOY-UHFFFAOYSA-N 0.000 description 1
- ZBXIRNVCPMZPFS-UHFFFAOYSA-N CC(C)(CCc(cc1)cc(OC(F)(F)F)c1O)N(C1)Cc2c1cccc2S(C)(=O)=O Chemical compound CC(C)(CCc(cc1)cc(OC(F)(F)F)c1O)N(C1)Cc2c1cccc2S(C)(=O)=O ZBXIRNVCPMZPFS-UHFFFAOYSA-N 0.000 description 1
- XNAGJLRFPOQPPM-UHFFFAOYSA-N CC(C)(CCc(cc1)cc(OC)c1O)N(C1)Cc2c1cccc2C(N1CCNCC1)=O Chemical compound CC(C)(CCc(cc1)cc(OC)c1O)N(C1)Cc2c1cccc2C(N1CCNCC1)=O XNAGJLRFPOQPPM-UHFFFAOYSA-N 0.000 description 1
- KBZZQJZAGBCNLA-UHFFFAOYSA-N CC(C)(CCc(cc1)ccc1OC)N(C1)Cc2c1cccc2C(N1CCNCC1)=O Chemical compound CC(C)(CCc(cc1)ccc1OC)N(C1)Cc2c1cccc2C(N1CCNCC1)=O KBZZQJZAGBCNLA-UHFFFAOYSA-N 0.000 description 1
- ZBSPPCBPRARDAO-UHFFFAOYSA-N CC(C)(CCc(cc1OC(F)(F)F)ccc1O)N(Cc1ccc2)Cc1c2C(O)=O Chemical compound CC(C)(CCc(cc1OC(F)(F)F)ccc1O)N(Cc1ccc2)Cc1c2C(O)=O ZBSPPCBPRARDAO-UHFFFAOYSA-N 0.000 description 1
- MXAUURQBNVRGPJ-UHFFFAOYSA-N CC(C)(CCc(cc1OC)ccc1OC)N(C1)Cc2c1cccc2C(N1CCNCC1)=O Chemical compound CC(C)(CCc(cc1OC)ccc1OC)N(C1)Cc2c1cccc2C(N1CCNCC1)=O MXAUURQBNVRGPJ-UHFFFAOYSA-N 0.000 description 1
- LJSPHZLEKKQLGW-UHFFFAOYSA-N CC(C)(CCc1cc(OC)ccc1)N(C1)Cc2c1cccc2C(N1CCNCC1)=O Chemical compound CC(C)(CCc1cc(OC)ccc1)N(C1)Cc2c1cccc2C(N1CCNCC1)=O LJSPHZLEKKQLGW-UHFFFAOYSA-N 0.000 description 1
- CZMKZNSLFDBBJT-UHFFFAOYSA-N CC(C)Oc1cc(CCC(C)(C)N(C2)Cc3c2cccc3F)ccc1O Chemical compound CC(C)Oc1cc(CCC(C)(C)N(C2)Cc3c2cccc3F)ccc1O CZMKZNSLFDBBJT-UHFFFAOYSA-N 0.000 description 1
- LZYHBBIARMIKJV-UHFFFAOYSA-N CC(C)Oc1ccc(CCC(C)(C)N(C2)Cc3c2ccc(F)c3)cc1OC(C)C Chemical compound CC(C)Oc1ccc(CCC(C)(C)N(C2)Cc3c2ccc(F)c3)cc1OC(C)C LZYHBBIARMIKJV-UHFFFAOYSA-N 0.000 description 1
- GAVBLSFCTDBORN-KRWDZBQOSA-N COC[C@H](CCc(cc1)cc(Cl)c1Cl)N1Cc2cc(F)ccc2C1 Chemical compound COC[C@H](CCc(cc1)cc(Cl)c1Cl)N1Cc2cc(F)ccc2C1 GAVBLSFCTDBORN-KRWDZBQOSA-N 0.000 description 1
- UYQJQXBCVBDUGX-LLVKDONJSA-N C[C@H](CCc(cc1)cc(Cl)c1Cl)N(C1)Cc(cc2Cl)c1cc2Cl Chemical compound C[C@H](CCc(cc1)cc(Cl)c1Cl)N(C1)Cc(cc2Cl)c1cc2Cl UYQJQXBCVBDUGX-LLVKDONJSA-N 0.000 description 1
- QOXCLDKXSCBOOF-CYBMUJFWSA-N C[C@H](CCc(cc1)cc(Cl)c1Cl)N(C1)Cc(cc2OC)c1cc2OC Chemical compound C[C@H](CCc(cc1)cc(Cl)c1Cl)N(C1)Cc(cc2OC)c1cc2OC QOXCLDKXSCBOOF-CYBMUJFWSA-N 0.000 description 1
- KTHLRNWGDXCNQL-GFCCVEGCSA-N C[C@H](CCc(cc1)cc(Cl)c1Cl)N(C1)Cc2c1cc1OCOc1c2 Chemical compound C[C@H](CCc(cc1)cc(Cl)c1Cl)N(C1)Cc2c1cc1OCOc1c2 KTHLRNWGDXCNQL-GFCCVEGCSA-N 0.000 description 1
- NTTVSJIWKNQHBI-GFCCVEGCSA-N C[C@H](CCc(cc1)cc(Cl)c1Cl)N(C1)Cc2c1ccc(F)c2 Chemical compound C[C@H](CCc(cc1)cc(Cl)c1Cl)N(C1)Cc2c1ccc(F)c2 NTTVSJIWKNQHBI-GFCCVEGCSA-N 0.000 description 1
- ZIDKNUHPKSUTKP-GFCCVEGCSA-N C[C@H](CCc(cc1)cc(Cl)c1Cl)N(C1)Cc2c1cccc2F Chemical compound C[C@H](CCc(cc1)cc(Cl)c1Cl)N(C1)Cc2c1cccc2F ZIDKNUHPKSUTKP-GFCCVEGCSA-N 0.000 description 1
- LEJPCSJGRRORSD-GFCCVEGCSA-N C[C@H](CCc(cc1)cc(Cl)c1Cl)N(Cc1ccc2)Cc1c2Cl Chemical compound C[C@H](CCc(cc1)cc(Cl)c1Cl)N(Cc1ccc2)Cc1c2Cl LEJPCSJGRRORSD-GFCCVEGCSA-N 0.000 description 1
- YKCVGPQFUBUSHV-CQSZACIVSA-N C[C@H](CCc(cc1)cc(Cl)c1Cl)N1Cc2cc(C)ccc2C1 Chemical compound C[C@H](CCc(cc1)cc(Cl)c1Cl)N1Cc2cc(C)ccc2C1 YKCVGPQFUBUSHV-CQSZACIVSA-N 0.000 description 1
- UBTJMMKDCGBMEX-CQSZACIVSA-N C[C@H](CCc(cc1)cc(OC(C)(C)C)c1O)N(Cc1c(cc2)F)Cc1c2F Chemical compound C[C@H](CCc(cc1)cc(OC(C)(C)C)c1O)N(Cc1c(cc2)F)Cc1c2F UBTJMMKDCGBMEX-CQSZACIVSA-N 0.000 description 1
- KWZTVVFHLUDCLT-OAHLLOKOSA-N C[C@H](CCc(cc1)cc(OC(C)(C)C)c1O)N(Cc1ccc2)Cc1c2F Chemical compound C[C@H](CCc(cc1)cc(OC(C)(C)C)c1O)N(Cc1ccc2)Cc1c2F KWZTVVFHLUDCLT-OAHLLOKOSA-N 0.000 description 1
- GLAFJHYUSDSQSZ-MRXNPFEDSA-N C[C@H](CCc(cc1)cc(OC(C)(C)C)c1O)N1Cc2cc(S(C)(=O)=O)ccc2C1 Chemical compound C[C@H](CCc(cc1)cc(OC(C)(C)C)c1O)N1Cc2cc(S(C)(=O)=O)ccc2C1 GLAFJHYUSDSQSZ-MRXNPFEDSA-N 0.000 description 1
- YYCFTPUSYYQXNV-GFCCVEGCSA-N C[C@H](CCc(cc1)cc(OC(F)(F)F)c1O)N(C1)Cc2c1cc1OCOc1c2 Chemical compound C[C@H](CCc(cc1)cc(OC(F)(F)F)c1O)N(C1)Cc2c1cc1OCOc1c2 YYCFTPUSYYQXNV-GFCCVEGCSA-N 0.000 description 1
- DKIOLBBRSOUKFN-GFCCVEGCSA-N C[C@H](CCc(cc1)cc(OC)c1O)N(C1)Cc(cc2Cl)c1cc2Cl Chemical compound C[C@H](CCc(cc1)cc(OC)c1O)N(C1)Cc(cc2Cl)c1cc2Cl DKIOLBBRSOUKFN-GFCCVEGCSA-N 0.000 description 1
- FUSCVNVOEODHTI-CYBMUJFWSA-N C[C@H](CCc(cc1)cc(OC)c1O)N(C1)Cc2c1cc1OCOc1c2 Chemical compound C[C@H](CCc(cc1)cc(OC)c1O)N(C1)Cc2c1cc1OCOc1c2 FUSCVNVOEODHTI-CYBMUJFWSA-N 0.000 description 1
- IKOFTAHOICQOFR-CYBMUJFWSA-N C[C@H](CCc(cc1)cc(OC)c1O)N(C1)Cc2c1ccc(F)c2 Chemical compound C[C@H](CCc(cc1)cc(OC)c1O)N(C1)Cc2c1ccc(F)c2 IKOFTAHOICQOFR-CYBMUJFWSA-N 0.000 description 1
- MVMPGBQFAWCGBD-CQSZACIVSA-N C[C@H](CCc(cc1)cc(OC)c1O)N(C1)Cc2c1ccc(S(C)(=O)=O)c2 Chemical compound C[C@H](CCc(cc1)cc(OC)c1O)N(C1)Cc2c1ccc(S(C)(=O)=O)c2 MVMPGBQFAWCGBD-CQSZACIVSA-N 0.000 description 1
- PPPGEPQJNAMZSS-CQSZACIVSA-N C[C@H](CCc(cc1)cc(OC)c1O)N(Cc1c2)Cc1cc(OC)c2OC Chemical compound C[C@H](CCc(cc1)cc(OC)c1O)N(Cc1c2)Cc1cc(OC)c2OC PPPGEPQJNAMZSS-CQSZACIVSA-N 0.000 description 1
- YYNYULNQESTNGR-CYBMUJFWSA-N C[C@H](CCc(cc1)cc(OC)c1O)N(Cc1ccc2)Cc1c2F Chemical compound C[C@H](CCc(cc1)cc(OC)c1O)N(Cc1ccc2)Cc1c2F YYNYULNQESTNGR-CYBMUJFWSA-N 0.000 description 1
- QGQPAGBSUNRRSW-OAHLLOKOSA-N C[C@H](CCc(cc1)cc(OC)c1OCCO)N(Cc1c2)Cc1cc1c2OCO1 Chemical compound C[C@H](CCc(cc1)cc(OC)c1OCCO)N(Cc1c2)Cc1cc1c2OCO1 QGQPAGBSUNRRSW-OAHLLOKOSA-N 0.000 description 1
- FCLQKBPRTZWHGX-OAHLLOKOSA-N C[C@H](CCc(cc1)cc(OC)c1OCCO)N1Cc2cc(F)ccc2C1 Chemical compound C[C@H](CCc(cc1)cc(OC)c1OCCO)N1Cc2cc(F)ccc2C1 FCLQKBPRTZWHGX-OAHLLOKOSA-N 0.000 description 1
- LFYNHAXLOHOWGV-CYBMUJFWSA-N C[C@H](CCc(cc1)ccc1F)N(C1)Cc2c1cccc2F Chemical compound C[C@H](CCc(cc1)ccc1F)N(C1)Cc2c1cccc2F LFYNHAXLOHOWGV-CYBMUJFWSA-N 0.000 description 1
- KZTQRGRPZOLMSL-CQSZACIVSA-N C[C@H](CCc(cc1OC(F)(F)F)ccc1OCCO)N1Cc2cc(F)ccc2C1 Chemical compound C[C@H](CCc(cc1OC(F)(F)F)ccc1OCCO)N1Cc2cc(F)ccc2C1 KZTQRGRPZOLMSL-CQSZACIVSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934528P | 2014-01-31 | 2014-01-31 | |
| US61/934,528 | 2014-01-31 | ||
| PCT/US2015/013754 WO2015116923A1 (en) | 2014-01-31 | 2015-01-30 | Isoindoline compositions and methods for treating neurodegenerative disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160108564A KR20160108564A (ko) | 2016-09-19 |
| KR102331422B1 true KR102331422B1 (ko) | 2021-11-25 |
Family
ID=53757753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167023951A Active KR102331422B1 (ko) | 2014-01-31 | 2015-01-30 | 아이소인돌린 조성물 및 신경퇴행성 질환을 치료하는 방법 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9796672B2 (https=) |
| EP (3) | EP3498692B1 (https=) |
| JP (1) | JP6517827B2 (https=) |
| KR (1) | KR102331422B1 (https=) |
| CN (1) | CN106163516B (https=) |
| AU (1) | AU2015210852B2 (https=) |
| BR (1) | BR112016017808B1 (https=) |
| CA (1) | CA2938212C (https=) |
| DK (2) | DK3498692T3 (https=) |
| ES (2) | ES2915833T3 (https=) |
| IL (1) | IL247003B (https=) |
| MX (1) | MX368755B (https=) |
| NZ (1) | NZ722599A (https=) |
| RU (1) | RU2692258C2 (https=) |
| WO (1) | WO2015116923A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014015197A8 (pt) | 2011-12-21 | 2017-06-13 | Novira Therapeutics Inc | agentes antivirais de hepatite b |
| KR102271574B1 (ko) | 2012-08-28 | 2021-07-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
| WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| MX353412B (es) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| TWI733288B (zh) | 2013-05-17 | 2021-07-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| HRP20180791T1 (hr) | 2013-07-25 | 2018-09-07 | Janssen Sciences Ireland Uc | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b |
| CA2923712C (en) | 2013-10-23 | 2021-11-02 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| RU2692258C2 (ru) | 2014-01-31 | 2019-06-24 | Когнишн Терапьютикс, Инк. | Композиции изоиндолина и способы лечения нейродегенеративного заболевания |
| CA2936947A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
| TW201620893A (zh) | 2014-02-06 | 2016-06-16 | 健生科學愛爾蘭無限公司 | 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途 |
| JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法 |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| TW201718496A (zh) | 2015-09-29 | 2017-06-01 | 諾維拉治療公司 | B型肝炎抗病毒劑之晶型 |
| EP3364976B1 (en) | 2015-10-19 | 2026-03-18 | Board of Regents, The University of Texas System | Piperazinyl norbenzomorphan compounds and methods for using the same |
| AU2017248828A1 (en) | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
| WO2017190109A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
| CN107162944B (zh) * | 2017-04-27 | 2019-02-26 | 湖南化工研究院有限公司 | 2,3-二甲基苯甲硫醚的制备方法 |
| DK3634394T3 (da) | 2017-05-15 | 2026-03-02 | Cognition Therapeutics Inc | Sammensætninger til behandling af neurogenerative sygdomme |
| WO2019089988A1 (en) * | 2017-11-01 | 2019-05-09 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| MX2020009531A (es) | 2018-03-14 | 2020-10-05 | Janssen Sciences Ireland Unlimited Co | Regimen posologico del modulador del ensamblaje de la capside. |
| JP6567153B1 (ja) * | 2018-09-28 | 2019-08-28 | 学校法人東北工業大学 | 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム |
| US20220009876A1 (en) * | 2018-10-31 | 2022-01-13 | Polycore Therapeutics Llc | Method for synthesizing d3 dopamine receptor agonists |
| WO2020169784A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
| CN111848466A (zh) * | 2019-03-08 | 2020-10-30 | 新昌县大船畈生物科技有限公司 | 一种食用香精香料的制备方法 |
| CN109734638A (zh) * | 2019-03-08 | 2019-05-10 | 新昌县大船畈生物科技有限公司 | 一种食用香精香料的制备方法 |
| AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| CN112694427B (zh) * | 2019-10-23 | 2022-11-18 | 江西天宇化工有限公司 | 一种制备2,3-二甲基苯甲硫醚的方法 |
| AU2021218735A1 (en) * | 2020-02-13 | 2022-09-01 | Cognition Therapeutics, Inc. | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
| IL298323B2 (en) | 2020-05-20 | 2023-10-01 | Univ Illinois | A method for treating lysosomal storage disease using histatin peptides |
| IL303592A (en) * | 2020-12-11 | 2023-08-01 | Cognition Therapeutics Inc | Compositions for treating dry age-related macular degeneration (amd) |
| EP4308565A4 (en) * | 2021-03-19 | 2025-01-01 | Cognition Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
| WO2024020059A1 (en) * | 2022-07-18 | 2024-01-25 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| WO2024130030A1 (en) * | 2022-12-14 | 2024-06-20 | Fred Hutchinson Cancer Center | Method for treating neurological diseases through glial pruning regulation |
| WO2024196799A2 (en) * | 2023-03-17 | 2024-09-26 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| CN117945980A (zh) * | 2024-01-24 | 2024-04-30 | 上海健康医学院 | 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用 |
| WO2026064543A1 (en) | 2024-09-18 | 2026-03-26 | Cognition Therapeutics, Inc. | Process for preparing 2-(tert-butoxy)-4-(3-methyl-3-(5-methylsulfonyl)isoindolin-2-yl)butyl)phenol |
| WO2026064542A1 (en) | 2024-09-18 | 2026-03-26 | Cognition Therapeutics, Inc. | 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts in solid forms |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013029057A2 (en) * | 2011-08-25 | 2013-02-28 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA732136B (en) | 1972-04-12 | 1974-03-27 | Lilly Co Eli | Dopamine derivatives |
| DE2753278A1 (de) | 1977-11-30 | 1979-05-31 | Basf Ag | Aralkylpiperidinone |
| US4321386A (en) | 1981-01-28 | 1982-03-23 | Mead Johnson & Company | Quaternary piperidinium halides |
| DE3222152A1 (de) | 1982-06-12 | 1983-12-15 | Bayer Ag, 5090 Leverkusen | Substituierte maleinsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
| IL70813A (en) | 1983-01-31 | 1987-10-30 | Lilly Co Eli | Animal feed comprising certain phenethanolamine derivatives and 1-phenyl-2-(1-methyl-3-(4-nitrophenyl)propylamino)ethanol hydrochloride |
| JPS62283922A (ja) | 1986-05-30 | 1987-12-09 | Tsumura Juntendo Inc | 血小板凝集抑制剤 |
| US4697024A (en) | 1986-11-24 | 1987-09-29 | Merrell Dow Pharmaceuticals Inc. | Medroxalol intermediates |
| US4958029A (en) * | 1987-01-13 | 1990-09-18 | Banyu Pharmaceutical Co., Ltd. | Process for the production of isoindoline derivatives, novel intermediates and process for their production |
| JPH01180822A (ja) | 1988-01-12 | 1989-07-18 | Dainippon Pharmaceut Co Ltd | 抗遅延型アレルギー剤 |
| JPH01305085A (ja) | 1988-05-31 | 1989-12-08 | Yamanouchi Pharmaceut Co Ltd | ピリジルチアゾリジンカルボン酸アミド誘導体 |
| JPH02215789A (ja) | 1989-02-15 | 1990-08-28 | Yamanouchi Pharmaceut Co Ltd | チアゾロ［３，４―ａ］ピラジン誘導体 |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| DE4000610A1 (de) | 1990-01-11 | 1991-07-18 | Knoll Ag | Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen |
| JP2818958B2 (ja) | 1990-02-23 | 1998-10-30 | 塩野義製薬株式会社 | ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法 |
| JPH045266A (ja) | 1990-04-24 | 1992-01-09 | Toyo Pharma- Kk | ドパミン誘導体の製造方法 |
| DE4142366A1 (de) | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| CN1192011C (zh) | 1991-08-23 | 2005-03-09 | Nps药物有限公司 | 对钙受体具活性的芳烷基胺化合物 |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
| CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
| JPH06321781A (ja) | 1993-05-13 | 1994-11-22 | Yamanouchi Pharmaceut Co Ltd | 血小板活性化因子拮抗剤 |
| ES2285707T3 (es) | 1994-10-21 | 2007-11-16 | Nps Pharmaceuticals, Inc. | Compuestos activos frente al receptor de calcio. |
| JPH0915744A (ja) | 1995-06-29 | 1997-01-17 | Fuji Photo Film Co Ltd | 磁気ヘッドの検査方法及びフィルムキャリア |
| JP3522930B2 (ja) | 1995-12-06 | 2004-04-26 | 花王株式会社 | 抗菌剤及びこれを含有する口腔用組成物 |
| WO1997030038A1 (en) | 1996-02-15 | 1997-08-21 | Mitsubishi Chemical Corporation | Diarylsultam derivatives |
| WO1997040051A1 (en) * | 1996-04-24 | 1997-10-30 | Takeda Chemical Industries, Ltd. | Fused imidazopyridine derivatives as antihyperlipidemic agents |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| US6518315B1 (en) | 1997-10-21 | 2003-02-11 | The University Of Sydney | Medicinal uses of phenylaikanols and derivatives |
| CO4980891A1 (es) | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
| CO5011072A1 (es) | 1997-12-05 | 2001-02-28 | Lilly Co Eli | Etanolaminas pirazinil substituidas como agfonistas de los receptores |
| IL138686A0 (en) | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
| WO2001030335A2 (en) | 1999-10-22 | 2001-05-03 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| DE10027151A1 (de) | 2000-05-31 | 2001-12-06 | Bayer Ag | Herbizide Mittel auf Basis von substituierten Carbonsäureamiden |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| ES2365602T3 (es) | 2001-03-05 | 2011-10-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Proteínas oligoméricas tipo chaperona, estables a desnaturalizantes y/o resistentes a proteasa, polinucleótidos que codifican las mismas y sus usos. |
| JP4312402B2 (ja) | 2001-07-31 | 2009-08-12 | 有限会社大長企画 | 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤 |
| US20030073681A1 (en) | 2001-08-21 | 2003-04-17 | Hauske James R. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
| US6991814B2 (en) | 2001-12-13 | 2006-01-31 | Council Of Scientific And Industrial Research | Herbal medicaments for the treatment of neurocerebrovascular disorders |
| EP1453528B1 (en) | 2001-12-14 | 2009-07-22 | Council of Scientific and Industrial Research | Compositions containing curcuma extracts for the treatment of neurocerebrovascular disorders |
| JP2004002517A (ja) | 2002-05-31 | 2004-01-08 | Dae Sil Kim | 生姜成分を含む石鹸の組成物及びその製造方法 |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| DE10320560A1 (de) | 2003-05-07 | 2004-01-29 | Brosig, Stefan, Dr. | Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit |
| EP1644026A4 (en) | 2003-06-12 | 2007-10-24 | Ms Science Corp | SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECREATION |
| US7829562B2 (en) | 2003-06-12 | 2010-11-09 | M's Science Corporation | Sigma ligands for neuronal regeneration and functional recovery |
| CZ2006628A3 (cs) | 2004-03-12 | 2007-01-24 | Egis Gyogyszergyár Nyrt. | Kombinovaná farmaceutická kompozice pro inhibici poklesu kognitivních funkcí |
| TW200538052A (en) | 2004-05-31 | 2005-12-01 | Kaneka Corp | Agent for preventing/amelioratig life style-relaetd diseases containing turmeric essential oil component |
| EP1794313B1 (en) | 2004-06-21 | 2013-05-15 | Proteome Sciences Plc | Screening methods using c-abl, fyn and syk in combination with tau protein |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| WO2006027252A1 (en) | 2004-09-10 | 2006-03-16 | Ucb Pharma, Sa | Sigma receptor ligands |
| US20080044356A1 (en) | 2004-10-22 | 2008-02-21 | Regents Of The University Of Minnesota | Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof |
| WO2006066118A2 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment |
| WO2006094724A2 (en) | 2005-03-05 | 2006-09-14 | Abbott Gmbh & Co. Kg | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
| KR20080041624A (ko) | 2005-06-15 | 2008-05-13 | 대릭 에스. 에치. 엘. 김 | 베타-아밀로이드 단백질-유발 안질환의 치료 방법 |
| TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
| EP1745778A3 (en) | 2005-07-20 | 2007-03-07 | Speedel Experimenta AG | Diaminoalcohols as therapeutic compounds |
| ITRM20060007A1 (it) | 2006-01-05 | 2007-07-06 | Univ Bari | Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici |
| US20070218491A1 (en) | 2006-02-08 | 2007-09-20 | Oligomerix, Inc. | Oligomerization of amyloid proteins |
| KR20090007564A (ko) | 2006-03-17 | 2009-01-19 | 허발사이언스 싱가포르 피티이 리미티드 | 쿠르쿠마 종을 포함한 추출물 및 이를 수득하는 방법 |
| WO2007112288A2 (en) | 2006-03-23 | 2007-10-04 | Mount Sinai School Of Medicine | Cardiovascular composition and use the same for the treatment of alzheimers disease |
| WO2007126473A2 (en) | 2006-04-10 | 2007-11-08 | Oligomerix, Inc. | Oligomerization of amyloid proteins |
| WO2008042024A2 (en) | 2006-06-01 | 2008-04-10 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
| US7561775B2 (en) | 2006-08-22 | 2009-07-14 | Senko Advanced Components, Inc. | Fiber optic protective shutter |
| CA2662723A1 (en) | 2006-09-08 | 2008-03-13 | Vib Vzw | Means and methods for the production of amyloid oligomers |
| WO2008042755A2 (en) | 2006-09-29 | 2008-04-10 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| US20080131233A1 (en) | 2006-10-17 | 2008-06-05 | Yao Chun I | Plate-shaped fastener device |
| WO2008076262A2 (en) | 2006-12-15 | 2008-06-26 | Merck & Co., Inc. | Receptor for amyloid beta and uses thereof |
| US20080171757A1 (en) | 2007-01-11 | 2008-07-17 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Serivces | Methods to identify inhibitors of cell sickling |
| EP2152744A4 (en) | 2007-04-26 | 2012-02-15 | Univ Yale | PRION PROTEIN AS RECEPTOR FOR AMYLOID-BETA OLIGOMERS |
| CA2684920A1 (en) | 2007-05-15 | 2008-11-27 | Helicon Therapeutics, Inc. | Methods of treating cognitive disorders by inhibition of gpr12 |
| CN101121670A (zh) | 2007-09-11 | 2008-02-13 | 上海紫源制药有限公司 | 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法 |
| US20090246191A1 (en) | 2007-10-11 | 2009-10-01 | University Of Tennessee Research Foundation | Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof |
| EP2206707B1 (en) | 2007-10-24 | 2014-07-23 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| WO2009059214A1 (en) | 2007-11-02 | 2009-05-07 | The Regents Of The University Of California | Abeta-binding small molecules |
| US20110092554A1 (en) | 2007-11-19 | 2011-04-21 | Richard Chesworth | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders |
| CN102203124A (zh) | 2008-07-25 | 2011-09-28 | 雅培制药有限公司 | 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途 |
| WO2010062260A1 (en) | 2008-11-29 | 2010-06-03 | The Thailand Research Fund | Virus and target cell interaction inhibition |
| WO2010088450A2 (en) | 2009-01-30 | 2010-08-05 | Celladon Corporation | Methods for treating diseases associated with the modulation of serca |
| AU2010226726B8 (en) | 2009-03-16 | 2014-08-14 | Pangu Biopharma Limited | Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities |
| US7972164B2 (en) | 2009-03-24 | 2011-07-05 | Tyco Electronics Corporation | Connector assembly with a latch |
| ES2545795T3 (es) * | 2009-04-09 | 2015-09-15 | Cognition Therapeutics, Inc. | Inhibidores del deterioro cognitivo |
| ES2581178T3 (es) | 2009-07-29 | 2016-09-01 | Pharnext | Nuevas herramientas de diagnóstico para enfermedad de Alzheimer |
| CN102595884B (zh) | 2009-07-31 | 2014-12-03 | 考格尼申治疗股份有限公司 | 认知衰退的抑制剂 |
| US20150160228A1 (en) | 2010-02-05 | 2015-06-11 | Susan Catalano | Compositions and method for determining the efficacy of amyloidosis treatments |
| WO2011106785A2 (en) | 2010-02-26 | 2011-09-01 | Cognition Therapeutics, Inc. | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| WO2012027548A1 (en) | 2010-08-25 | 2012-03-01 | The Feinstein Institute For Medical Research | Compounds and methods for prevention and treatment of alzheimer's and other diseases |
| BR112013019775A2 (pt) | 2011-02-02 | 2017-04-18 | Cognition Therapeutics Inc | composto, composição farmacêutica e método para tratar declínio cognitivo ou doença de alzheimer em um paciente |
| US20170049723A1 (en) | 2011-02-02 | 2017-02-23 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
| EP2747768A4 (en) | 2011-08-25 | 2015-10-21 | Cognition Therapeutics Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| AT511906B1 (de) | 2011-08-30 | 2016-05-15 | Blum Gmbh Julius | Schublade |
| WO2015020523A1 (en) | 2013-08-07 | 2015-02-12 | Stichting Vu-Vumc | Biomarkers for early diagnosis of alzheimer's disease |
| RU2692258C2 (ru) | 2014-01-31 | 2019-06-24 | Когнишн Терапьютикс, Инк. | Композиции изоиндолина и способы лечения нейродегенеративного заболевания |
| DK3634394T3 (da) | 2017-05-15 | 2026-03-02 | Cognition Therapeutics Inc | Sammensætninger til behandling af neurogenerative sygdomme |
| WO2019089988A1 (en) * | 2017-11-01 | 2019-05-09 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| CN110283082A (zh) | 2019-07-15 | 2019-09-27 | 泰州职业技术学院 | 一种3-苯基丙胺的制备方法 |
| AU2021218735A1 (en) * | 2020-02-13 | 2022-09-01 | Cognition Therapeutics, Inc. | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
| IL303592A (en) | 2020-12-11 | 2023-08-01 | Cognition Therapeutics Inc | Compositions for treating dry age-related macular degeneration (amd) |
-
2015
- 2015-01-30 RU RU2016134677A patent/RU2692258C2/ru active
- 2015-01-30 EP EP19154222.4A patent/EP3498692B1/en active Active
- 2015-01-30 CA CA2938212A patent/CA2938212C/en active Active
- 2015-01-30 EP EP22155541.0A patent/EP4023294A1/en active Pending
- 2015-01-30 DK DK19154222.4T patent/DK3498692T3/da active
- 2015-01-30 ES ES19154222T patent/ES2915833T3/es active Active
- 2015-01-30 KR KR1020167023951A patent/KR102331422B1/ko active Active
- 2015-01-30 NZ NZ722599A patent/NZ722599A/en unknown
- 2015-01-30 ES ES15743281T patent/ES2721001T3/es active Active
- 2015-01-30 JP JP2016549224A patent/JP6517827B2/ja active Active
- 2015-01-30 US US15/115,187 patent/US9796672B2/en active Active
- 2015-01-30 CN CN201580017497.0A patent/CN106163516B/zh active Active
- 2015-01-30 DK DK15743281.6T patent/DK3099296T3/en active
- 2015-01-30 BR BR112016017808-4A patent/BR112016017808B1/pt active IP Right Grant
- 2015-01-30 MX MX2016009845A patent/MX368755B/es active IP Right Grant
- 2015-01-30 WO PCT/US2015/013754 patent/WO2015116923A1/en not_active Ceased
- 2015-01-30 AU AU2015210852A patent/AU2015210852B2/en active Active
- 2015-01-30 EP EP15743281.6A patent/EP3099296B1/en active Active
-
2016
- 2016-07-28 IL IL247003A patent/IL247003B/en active IP Right Grant
-
2017
- 2017-09-11 US US15/700,923 patent/US10207991B2/en active Active
-
2018
- 2018-12-21 US US16/230,238 patent/US10611728B2/en active Active
-
2020
- 2020-02-06 US US16/783,943 patent/US11691947B2/en active Active
-
2023
- 2023-04-27 US US18/308,037 patent/US12466795B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013029057A2 (en) * | 2011-08-25 | 2013-02-28 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102331422B1 (ko) | 아이소인돌린 조성물 및 신경퇴행성 질환을 치료하는 방법 | |
| JP2017206545A (ja) | 神経変性疾患を処置する組成物及び方法 | |
| JP2014529613A (ja) | 神経変性疾患を治療する組成物及び方法 | |
| EP3634394B1 (en) | Compositions for treating neurodegenerative diseases | |
| HK40010047A (en) | Isoindoline compositions and methods for treating neurodegenerative disease | |
| HK40010047B (en) | Isoindoline compositions and methods for treating neurodegenerative disease | |
| HK1225651B (zh) | 异吲哚啉组合物和治疗神经变性疾病的方法 | |
| WO2026030341A1 (en) | Zervimesine for treating neurodegenerative disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20160830 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200129 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210623 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20210902 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20211123 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20211123 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20241029 Start annual number: 4 End annual number: 4 |